HumanN "Russian Vaccine CoviVac Development Team Visits Korea"

[Asia Economy Reporter Hyunseok Yoo] HumanN announced on the 15th that key personnel from the Chumakov Institute of Poliomyelitis and Viral Encephalitides (Chumakov Institute), which developed the COVID-19 vaccine 'Covivac,' arrived in Korea on the 12th.

The visit of the Chumakov Institute officials to Korea was made at the invitation of MP Corporation (MPC), in which HumanN and Wellbiotech each invested 7 billion KRW. MPC is a special purpose company (SPC) responsible for overseeing the Covivac business in Korea.

The Chumakov Institute plans to discuss with MPC the application for emergency use authorization of Covivac in Korea. Covivac is an inactivated virus vaccine for COVID-19 developed by the Chumakov Institute, which obtained approval for use in Russia last February.

The company explained that immediately after the domestic emergency use authorization application is completed, MPC will actively collaborate with HumanN and Wellbiotech to advance the project.

Established in 1957, the Chumakov Institute is the only developer of poliovirus vaccine technology in Russia and is registered as a vendor with the World Health Organization (WHO) and UNICEF. It was the first in Russia to develop a tick-borne encephalitis vaccine and has received seven of the 111 vaccines issued with Russian national medical registration certificates.

Meanwhile, according to the Chumakov Institute, Covivac is an inactivated vaccine developed by combining traditional vaccine manufacturing methods with modern technology, significantly reducing the risk of side effects. It secured reliability in immunogenicity through preclinical and Phase 1 and 2 clinical trials, and in Phase 2 clinical trials, it demonstrated safety, efficacy, and approximately 92% effectiveness in preventing COVID-19.

This content was produced with the assistance of AI translation services.